HomeIMGN • BMV
ImmunoGen Ord Shs
$268.50
Mar 27, 2:23:09 PM GMT-6 · MXN · BMV · Disclaimer
StockMX listed securityUS headquartered
Previous close
$268.50
Year range
$101.20 - $330.00
Market cap
8.72B USD
P/E ratio
-
Dividend yield
-
Market news
Financials
Income Statement
Revenue
Net income
(USD)Sep 2023Y/Y change
Revenue
113.42M637.72%
Operating expense
37.74M12.26%
Net income
30.75M139.54%
Net profit margin
27.11105.36%
Earnings per share
0.10132.26%
EBITDA
26.38M134.26%
Effective tax rate
-3.94%
Total assets
Total liabilities
(USD)Sep 2023Y/Y change
Cash and short-term investments
605.54M95.64%
Total assets
822.10M129.13%
Total liabilities
260.50M44.09%
Total equity
561.60M
Shares outstanding
266.26M
Price to book
127.25
Return on assets
8.45%
Return on capital
10.62%
Net change in cash
(USD)Sep 2023Y/Y change
Net income
30.75M139.54%
Cash from operations
2.77M104.31%
Cash from investing
-1.35M-124.92%
Cash from financing
32.13M7,056.35%
Net change in cash
33.55M152.12%
Free cash flow
-2.40M91.49%
About
ImmunoGen, Inc. was a biotechnology company focused on the development of antibody-drug conjugate therapeutics for the treatment of cancer. ImmunoGen was founded in 1981 and was headquartered in Waltham, Massachusetts. An ImmunoGen ADC contains a manufactured antibody that binds to a target found on cancer cells, with one of the company's potent cell-killing agents attached as a "payload". The antibody serves to deliver the cell-killing agent specifically to cancer cells bearing its target and the payload serves to kill these cells. In some cases, the antibody also has anticancer activity. In November 2023, AbbVie, an American pharmaceutical company, announced it was buying ImmunoGen for 10.1 billion. Wikipedia
Founded
1981
Employees
277
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Google apps
Main menu